SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Great Basin Scientific Inc. (GBSN)

Add GBSN Price Alert      Hide Sticky   Hide Intro
Moderator: Atlanta1, EnergySaver, TKane, jdporter, kontente
Search This Board: 
Last Post: 5/25/2017 9:08:39 PM - Followers: 441 - Board type: Free - Posts Today: 43



PHONE: 801-990-1055; TOLLFREE: 888-360-4022; CUSTOMER SUPPORT: 888-333-9793

***5/24/2017 NEWS UPDATE*** 

Great Basin Scientific Issued Second U.S. Patent for PCR Amplification Suppressor

SALT LAKE CITY, May 24, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc.(OTCQB:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,657,353 for the Company’s amplification suppressor. This patent is the second U.S. patent relating to Great Basin’s amplification suppressor technology, expanding the Company’s protection to assays, kits, and products. The protection afforded by this patent allows the Company to explore licensing of the technology to applications such as medical research, food safety, veterinary, and more.

“Environmental contamination by Staphylococcus species or any other bacteria environmental contaminant of clinical samples—producing false positive results—is a problem that has stymied the molecular diagnostics industry since its beginning, which was the impetus for our development of this technology,” said Robert D. Jenison, chief technology officer of Great Basin Scientific. “We believe our amplification suppressor is an important scientific advancement in its ability to fully suppress non-life-threatening environmental contaminants from a clinical sample. This important technology enables us to seek licensing opportunities with molecular diagnostics companies that operate outside of our market niche, and aligns with our growth strategy to broaden our revenue stream.” The technology, currently utilized in the Company’s Staph ID/R Blood Culture Panel, distinguishes between Staphylococcus species present in a clinical sample from a Staphylococcus contamination that is introduced during the sample collection or testing process. While not negatively impacting the appropriate clinical assay limit of detection, Great Basin’s technology completely blocks detection of contaminants present in the environment that may lead to a false positive result and potential misdiagnosis of a patient.  A study, which was led by Jenison and published in the April issue of PLOS ONE, showed that the Company’s amplification suppressor completely blocked environmental contaminants in a clinical sample that were detected at rates as high as 40%. The full study can be accessed here. The new patent protects Staphylococcus-based products, including nasal swabs and pre-surgical screens, such as methicillin-resistant Staphylococcus aureus (MRSA) screens. Great Basin’s Staph ID/R Blood Culture Panel is the Company’s first commercial embodiment of the patented amplification suppressor technology. In addition to being used in its Staph ID/R Blood Culture Panel, the amplification suppressor technology is being utilized in the Company’s in-development SA Nasal Screen Test, and is expected to be used in future tests and panels. With this patent, Great Basin has eight U.S. patents issued, with 11 additional patents pending. Great Basin’s molecular diagnostics system offers low-, mid-plex and multiplex testing, with commercial assays available for the detection of Shiga Toxin-producing Escherichia coli (STEC), Group B Streptococcus (GBS), Toxigenic Clostridium difficile (C. diff), Bordetella pertussis, and a Staph ID/R Blood Culture Panel (SIDR) for identifying bloodstream infections caused by MRSA and other Staphylococcus species. Additionally, the Company is awaiting 510(k) clearance from the U.S. Food & Drug Administration (FDA) on a Stool Bacterial Pathogens Panel. Other tests in development include a direct-from-blood Candida Blood Infections Panel, a CT/NG/TV Test, and a Nasal S. aureus Pre-surgical Screen Test.

***4/12/2017 NEWS UPDATE***

Announced today (4/12/2017) that it has received CE Marking for its Stool Bacterial PathogensPanel

***4/3/2017 NEWS UPDATE*** 

FDA 510(k) Premarket Notification - Effective 3/31/2017 - Great Basin Scientific, Inc. - Bordetella Pertussis DNA Assay System:

FYI (Why this particular diagnostic product is so important and useful for healthcare professionals): Pertussis, a respiratory illness commonly known as whooping cough, is a very contagious disease caused by a type of bacteria called Bordetella pertussis. These bacteria attach to the cilia (tiny, hair-like extensions) that line part of the upper respiratory system. The bacteria release toxins (poisons), which damage the cilia and cause airways to swell. Pertussis is a very contagious disease only found in humans. It is spread from person to person. People with pertussis usually spread the disease to another person by coughing or sneezing or when spending a lot of time near one another where you share breathing space. Many babies who get pertussis are infected by older siblings, parents, or caregivers who might not even know they have the disease.

GBSN's most recent 510(k) clearances and applications: 

Great Basin Scientific, Inc. (GBSN) granted 510(k) clearance 3/31/17 by the FDA for Great Basin Bordetella Direct Test

Great Basin Scientific, Inc. submits 510(k) application to FDA 12/19/16 for diagnostic Stool Bacterial Pathogens Panel.

Great Basin Scientific Reports Fourth Quarter and Full Year 2016 Results
(GlobeNewswire,  March 22, 2017, 07:03:00 AM EDT)

*Company reduces operating costs, improves gross margin and cash burn rate quarter-over-quarter *
Fourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%
14% reduction in net cash used in operating activities from the third quarter to the fourth quarter of 2016
34% reduction in fourth quarter G&A expenses leads to 4% reduction in total operating expenses compared to third quarter
Quarterly gross margin improved 42 basis points over third quarter to best level of the year
Percentage of customers using more than one assay increased 17% quarter-over-quarter and 81% year-over-year

SALT LAKE CITY, March 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:

GBSN), a molecular diagnostic company, today reported operating results for the fourth quarter and full year ended December 31, 2016.

"The fourth quarter of 2016 was a period of significant progress and change for Great Basin," said Ryan Ashton, co-founder and chief executive officer of Great Basin. "During the third quarter, research and development spending and gross margin inefficiency peaked as we invested in significant menu expansion, which included concurrently running two clinical trials and preparing for the commercial launch of two products that the U.S. Food and Drug Administration (FDA) cleared in early 2016. With those efforts either behind us or winding down, we turned our focus to improving operational efficiencies and implementing cost management programs in preparation for 2017. These efforts resulted in a reduction in sequential quarterly operating expenses and our strongest gross margins of the fiscal year. Furthermore, we expect that the changes we made in the fourth quarter—along with the January completion of the clinical trial for our Bordetella Direct Test and the restructuring and reduction plan we announced in early February—will result in further improvements to our operating expenses, burn rate and gross margins in the first half of 2017."

"Beyond the sequential improvements in gross margins and reduced operating expenses, 2016, overall, was a year of noteworthy progress for the Company. For the first time, we launched two new products and successfully completed two clinical trials in a single year. The doubling of our menu to four assays will promote our objective of continually expanding our customer footprint and increasing our revenue per customer."

Read more:







About Great Basin Scientific, Inc: Great Basin Scientific, Inc. (ticker symbol: GBSN) is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin's molecular diagnostics system is uniquely capable of answering both the ‘What is it?’ question --answered by a low-cost, low-plex assay-- and the ‘What is causing it?’ question, identified by a multi-plex panel. Great Basin has FDA Clearance on tests for Clostridium difficile and Group B streptococcus. Low-plex tests in development include SA Nasal and Staph ID/R and multi-plex panels being developed include Fungal Pathogens, Shiga-toxin-producing E. coli (STEC) and Food-borne Pathogens (GI Panel). Great Basin Scientific’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. Fast, accurate results. More answers. One easy-to-use and cost-effective system. Only Great Basin delivers a powerful product pipeline of tests and panels that allows every lab to adopt molecular diagnostics that will assist clinicians in better diagnosing and managing patients outcomes. The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. Great Basin Scientific, Inc. is headquartered in Salt Lake City, UT. For more information on the company or its products, please feel free to contact us at our Corporate Headquarters.


Amended Statement of Ownership (sc 13g/a)
Date: January 24, 2017 @ 4:29 PM
Source: EDGAR (US Regulatory)
Stock: Great Basin Scientific, Inc. (QB) (GBSND)

 All iHub stock board posts are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting any content that is off-topic to the stock, which is the subject of the board;
*Posting focused on Admins, Moderators, Users, or post deletions are also off-topic;
*Posting comments, etc. that could be construed as a Personal Attack on another;
*Posting anything that is a Violation of Privacy (no stated consent) is also off-topic;

* Posting statements that are of no value to the stock discussion for board users; or
* When you violate any other posting term of the iHub User Agreement:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
GBSN News: Current Report Filing (8-k) 04/10/2017 09:02:48 AM
GBSN News: USMJ Experiencing High Volume On Verge Of PPS Breakout With Stock Rated Very Bullish And Major Short Position Getting Squeezed 04/06/2017 11:49:40 AM
GBSN News: Annual Report (10-k) 03/22/2017 07:18:09 AM
GBSN News: Current Report Filing (8-k) 03/22/2017 07:01:46 AM
GBSN News: Current Report Filing (8-k) 03/10/2017 07:17:42 AM
#36774  Sticky Note Great Basin Scientific Obtains Release of $1.36 Million Lexi2vic 05/15/17 08:32:23 AM
#35684  Sticky Note News: Should trigger a lit sdtrader77 04/12/17 07:13:08 AM
#31968  Sticky Note Great Basin Scientific Receives FDA 510(k) Clearance for kontente 04/04/17 09:20:53 AM
#36940   the 52 week high is 119 million??????? ecmoney 05/25/17 09:08:39 PM
#36939   Smartest American Ashton from SLC!!!!!!!!!!!!!!! Id StockUser 05/25/17 06:21:04 PM
#36938   Looks like Ashton is saving $. No PR, Id StockUser 05/25/17 06:15:51 PM
#36937   Only dilution but won't go BANKRUPT 4 now!! Id StockUser 05/25/17 05:52:31 PM
#36936   the company is bankrupt !!!!! The_BORG 05/25/17 05:43:55 PM
#36935   lol..Ryan Ashton!! All da way 2 LA!! No stopping!! Id StockUser 05/25/17 05:17:23 PM
#36934   yep - he's not a crook, just an Atlanta1 05/25/17 05:06:52 PM
#36933   Ryan Ashton is doing everything within the SEC LAW!! Id StockUser 05/25/17 05:03:12 PM
#36930   GBSND in America? lol...This business model will eat Id StockUser 05/25/17 04:53:18 PM
#36928   Didn't the company announced a stop of note naturalborninvestor 05/25/17 04:39:46 PM
#36927   Any bad news? Or this is normal behavior Vis567 05/25/17 04:27:52 PM
#36926   And the best is !!! this 5 Million The_BORG 05/25/17 03:41:53 PM
#36925   Minimum 40-50% off soon!!!! Watch OUT!! Id StockUser 05/25/17 03:17:27 PM
#36924   Ashton is shortly for his bankrupt, so he The_BORG 05/25/17 03:17:14 PM
#36923   We need another RS Pronto! dandan2x72 05/25/17 02:23:08 PM
#36922   But we must clearly distinguish. The_BORG 05/25/17 01:57:43 PM
#36921   GBSN finally back to normal I was wondering wickerman 05/25/17 01:48:24 PM
#36920   insider buying, a big dream from Ashton ***lol The_BORG 05/25/17 01:07:22 PM
#36919   They r cashing out whatever they can as always!!! Id StockUser 05/25/17 01:05:38 PM
#36918   Wowwww this is such a scam. How Tbone88 05/25/17 12:56:32 PM
#36917   The lenders can't be happy if they are trd4profit 05/25/17 12:51:14 PM
#36916   now fake-bids from ashton that he find buyer The_BORG 05/25/17 12:47:49 PM
#36915   who gets all this money where does it chris12 05/25/17 12:30:35 PM
#36914   ***lol hey Ashton sell 15k in 1 hour ***lol The_BORG 05/25/17 12:00:48 PM
#36913   this company go bankrupt in the next few weeks/months... The_BORG 05/25/17 11:33:14 AM
#36912   Smartest CEO, Ryan Ashton!!! The king of dilution!!! Id StockUser 05/25/17 11:26:59 AM
#36911   Agreed TB. Ashton has proven all of this. TKane 05/25/17 11:26:48 AM
#36910   No bankruptcy here in da short term, they Id StockUser 05/25/17 11:24:52 AM
#36909   it´s doesn't matter for those pair of bucks... The_BORG 05/25/17 11:13:35 AM
#36907   He Ashton you Looser !!! :-) The_BORG 05/25/17 10:43:19 AM
#36906   Ashton loves 3 things: R/S, dilution, cash. Proven. TKane 05/25/17 10:25:35 AM
#36905   Ashton is smart !??? The_BORG 05/25/17 10:24:32 AM
#36904   And the current CRATERING is because of the BRoberts1982 05/25/17 10:17:31 AM
#36903   chart looks bad Poor Trader 05/25/17 10:17:26 AM
#36901   I don't think you read my post or BRoberts1982 05/25/17 10:11:14 AM
#36900   This script, this play, this orchestrated plan, by Emptyhead 05/25/17 10:05:48 AM
#36899   on Monday we stay at 10 cents with The_BORG 05/25/17 10:01:08 AM
#36898   5 million shares over a buck huh? Not trd4profit 05/25/17 09:53:52 AM
#36897   WOW. WTF HAPPENED TO THE PPS ON THE towerclimber92 05/24/17 07:10:32 PM
#36896   Straight to LA, no stopping! Id StockUser 05/24/17 05:00:29 PM
#36895   IMO this stock is worse than gambling unless Id StockUser 05/24/17 04:56:54 PM
#36894   He's been doing this ever since day 1 Id StockUser 05/24/17 04:53:37 PM
#36893   Which scares me so ... the guy is The_BORG 05/24/17 04:21:15 PM
#36892   My friend...Best is yet 2 come, it's just Id StockUser 05/24/17 04:10:03 PM
#36891  Restored what for a looser this asshole !!!! The_BORG 05/24/17 04:05:05 PM
#36890   Congrats Ashton!!!!! New All Time Low!!!! Id StockUser 05/24/17 03:53:34 PM
#36889   come one Ashton kick 100K to the bid The_BORG 05/24/17 03:48:40 PM
#36888   common ashton kick 20k more in the bid The_BORG 05/24/17 03:43:56 PM
#36887   #1 Company with All Star CEO & Sandra!!! TDM!! Id StockUser 05/24/17 03:15:49 PM